SYGNIS Granted US Patent for QUALIPHI®
Complete the form below to unlock access to ALL audio articles.
SYGNIS Pharma AG has been granted a patent by the USPTO (US patent and Trademark office) for its flagship product, QUALIPHI® the polymerase for complete DNA amplification.
Polymerase proteins are the main tool for amplifying long DNA fragments and whole genomes, and are a basic need for research involving the analysis and modification of DNA.
QUALIPHI® is an upgraded version of the Phi 29 DNA polymerase used in isothermal amplification which provides enhanced properties compared to similar polymerase proteins on the market.
Being less time-consuming and having highly superior performance characteristics, the method developed by SYGNIS enables DNA amplification from concentrations as low as those found in a single cell. This is extremely useful in cancer research, and many other applications.
“Certainly, the need for amplification of nucleic acids from minimal concentrations as present in single cell applications will be a critical issue in the coming era of personalized medicine and NGS. We expect QUALIPHI® to become an essential tool for the DNA amplification needed in these markets”, said SYGNIS’ CEO, Pilar de la Huerta.
With the significant growth in the field of DNA amplifications used in sequencing and personalized medicine, the market of whole genome amplification with polymerase proteins is expected to grow at over 20% per annum over the next few years.
Current estimates indicate that the size of the global isothermal DNA market alone is approximately €70 million, with the US as the leading market for QUALIPHI®.
In 2012,SYGNIS granted an exclusive global licence to QIAGEN, including sublicensing rights, for the commercialization of QUALIPHI® in the DNA amplification market. QIAGEN is a global leader in sample and assay technologies in research and molecular diagnostics.
